News
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement ...
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
Moderna Inc. gained US approval for a new Covid vaccine for a narrower group of people, in the latest sign that regulators ...
The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...
Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...
FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...
The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...
The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results